This document discusses meibomian gland dysfunction (MGD), including its definition, prevalence, anatomy, pathophysiology, clinical evaluation, treatment options, case examples, and billing considerations. Key points include: MGD is a chronic abnormality of the meibomian glands characterized by terminal duct obstruction and/or changes in glandular secretion, which can result in dry eye symptoms and ocular surface disease. Evaluation involves assessing symptoms, eyelids, meibomian glands, tear film, and ocular surface. Treatment options include topical medications, oral antibiotics, in-office procedures like gland expression, and home lid hygiene. Emerging therapies and the importance of understanding MGD are also emphasized.